Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:524 (28 February), doi:10.1136/bmj.328.7438.524-a
| The first 150 words of the full text of this article appear below. |
EDITORMhlongo and Maduna and Prime et al challenge the results of our study and think that we overlooked alternative reasons for the rapid fivefold decline in mortality, progression to AIDS, and hospital admission rates we reported in the CHIPS cohort of vertically HIV infected children in the United Kingdom and Ireland. We cannot agree that they provide viable alternative explanations for the dramatic reduction.
Firstly, we did not include details of management of opportunistic infections, and we agree that there is indirect evidence that cotrimoxazole prophylaxis reduces the frequency of these (particularly Pneumocystis carinii pneumonia in infancy, as previously reported in the United Kingdom1). This does not explain the magnitude or the timing of the effect we observed; cotrimoxazole prophylaxis has been widely used in HIV infected children in the United Kingdom and Ireland since the early 1990s, as evidenced by its inclusion in guidelines in 1994,
D M Gibb, reader in epidemiology
mbh@ctu.mrc.ac.uk, Medical Research Council Clinical Trials Unit, London NW1 2DA
T Duong, statistician
Medical Research Council Clinical Trials Unit, London NW1 2DA
P A Tookey, senior lecturer in paediatric epidemiology
Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London WC1N 1EH